CLIC-INNOVATION
27.8.2024 13:08:28 CEST | Business Wire | Press release
Rare earth elements and rare magnets play a crucial role in advancing the green energy transition and achieving the goals of the European Green Deal. While the EU currently relies heavily on imports from a few countries— with approximately 90% of REEs* coming from outside the EU—this presents an opportunity to develop European expertise and forge strategic partnerships in rare earth metals processing. Strengthening these capabilities within Europe is key to reaching our ambitious targets. Additionally, while challenges remain in REEs recycling, with current rates being less than 5% and some extraction processes needing sustainability improvements, these challenges also present a significant potential for innovation and growth. As demand for REEs increases, driven by their use in electric vehicles, wind turbine motors, and electrolysers for clean hydrogen, there is a tremendous opportunity to enhance recycling efforts and establish more sustainable extraction processes within the EU.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240827785891/en/
CLIC Innovation: REMHub Project Develops a Digital Innovation Hub for Rare Earth Elements and Rare Magnets (Copyright (c) 2024 Phawat/Shutterstock)
Project targets and development areas
REMHub will develop, test and pilot novel technologies for the exploration and primary production of rare earth elements and for recovering them from side streams to enhance supply security of REEs and rare magnets in the EU. In addition, the project will develop Re-X (Recycle, Reuse, refurbishment and repurposing) technologies for rare earths and valuable metals from end-of-life products as well as electric machine design for easier permanent magnet recycling. The project will also identify and engage relevant stakeholders to develop REE value chains in the EU. The innovation hub will ensure that the novel technologies developed in the project will be commercialized and offered as services via digital platform in the future.
The project’s multi-stakeholder communication and dissemination efforts are designed to actively involve and engage the public and various stakeholders, fostering trust and raising awareness about the importance of REEs. These activities also aim to build essential capacities within the EU. The hub focuses on transformative material sourcing for REEs and REE magnets, including innovations in traceability, digital twinning, and digital passports. Our project partners span the entire REE value chain, from mineral exploration and processing to metal production, magnet manufacturing, and recycling.
The project is committed to a safe and sustainable by design (SSbD) framework, embracing a Re-X approach that prioritizes recycling, reuse, refurbishment, and repurposing, while integrating features for easy dismantling and circularity. REMHub is set to significantly enhance the security of REE supply in the EU. With the support of our digital innovation hub, it will accelerate the development of technologies and services, enabling faster and easier market entry. By the conclusion of the project, future organizations will find it much easier to access sustainably developed REE expert services within the EU.
Project in a nutshell
The project will commence at the beginning of October and last for four years. The project consortium consists of 24 partners from six countries: Finland, Estonia, Spain, Ireland, Slovenia, and Italy. The project preparation and consortium coordination were led by the Finnish organization CLIC Innovation, which also serves as the project coordinator. The estimated total volume of the project is 18 million euros, of which 16 million euros is EU funding. The EU Horizon "resilient value chains" funding instrument supports European sustainable development value chain projects with financing from the European Commission.
* source: https://scrreen.eu/wp-content/uploads/2023/08/SCRREEN2_factsheets_REE-EUROSTAT.pdf
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240827785891/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
